Educational Webinar Series
The Pfizer Vaccines US Medical Affairs Team invites you to attend an educational webinar series titled
Translating mRNA, which is focused on providing education on COVID-19 and vaccination. The webinar series is designed to communicate scientific information, including recent study results to support healthcare providers’ knowledge regarding Pfizer and BioNTech’s COVID-19 vaccines.
The webinar series will include a live question-and-answer session with Pfizer medical experts.
We are hosting a Translating mRNA session on the topic below
Early Estimates of Updated 2023–2024 COVID-19 Vaccines Effectiveness
Date and Time:
Thursday, 22 February 2024: 12:00 pm – 12:30 pm ET
Speaker: Rajeev M Nepal, PhD
Medical Director, Pfizer mRNA Vaccines, Medical and Scientific Affairs, USA
Target Audience: All healthcare professionals including but not limited to physicians, nurse practitioners, pharmacists, and physician assistants.
Continuing medical education credit is NOT associated with this event.
Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula) has not been approved or licensed by FDA, but has been authorized for emergency use by FDA, under an EUA to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 6 months through 11 years of age. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b) (1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner.
For most recent Fact Sheets, please visit www.cvdvaccine-us.com